Aduro's pancreatic cancer drug fails in mid-stage study

May 16 (Reuters) - Aduro Biotech Inc said its

pancreatic cancer drug did not improve overall survival in

patients who did not show improvement after at least two prior

therapies, in a mid-stage study.

Read more